Company Overview and News

 
Kwun Tong residential site attracts 25 bids despite concerns over infrastructure capacity

2018-01-19 scmp
Developers’ enthusiasm for land tenders has shown no signs of easing – a residential site in Hong Kong’s Kwun Tong has attracted stronger than expected interest. But valuers said infrastructure in the region might not be able to support the extra population.

 
Hong Kong land prices baffle billionaire developer

2016-09-08 scmp
After more than 50 years as a Hong Kong developer, octogenarian billionaire Lui Che-Woo says he’s having trouble reading the city’s property market these days.

 
Hong Kong land prices baffle developer with 50 years' experience

2016-09-08 theedgemarkets
HONG KONG (Sept 8): After more than 50 years as a Hong Kong developer, octogenarian billionaire Lui Che-Woo says he’s having trouble reading the city’s property market these days.

 
Hong Kong Land Prices Baffle Tycoon With 50 Years Experience - Bloomberg

2016-09-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Mainland buyers splash out HK$58b+ on assets and land in Hong Kong as yuan devaluation fears linger

2016-08-10 scmp
And the acquisitions are likely to continue, say experts, as city remains favourite investment destination amid growing uncertainties in Europe

 
Mainland developers loosen purse strings to snap up prime real estate in Hong Kong

2016-08-09 scmp
Cash-rich developers from the mainland are on a shopping spree in Hong Kong and are leaving no stone unturned to corner prime real estate in the city.

 
Hong Kong Ferry, Walter Kwok team up to land HK$2.7 billion residential site in Tuen Mun

2016-08-08 scmp
Hong Kong Ferry has teamed up with former Sun Hung Kai Properties (SHKP) chairman Walter Kwok Ping-sheung to place the winning bid for a residential site in Tuen Mun at 17 per cent above the high-end of market expectations.

 
Minmetals buys record HK$4 billion site in Yau Tong

2016-08-03 scmp
Hong Kong-listed mainland developer Minmetals Land has paid HK$7,000 per square foot for a residential site in Yau Tong, a record price for a traditional industrial area.

 
Latest SOE property marriage suggests pace of realty consolidation will quicken

2016-07-07 scmp
But as Poly Real and AVIC join forces, some fear more-powerful players will only intensify competition for land

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...